19:22 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

AOBiome reports Phase IIb data of ammonia-oxidizing bacteria candidate for acne

AOBiome LLC (Cambridge, Mass.) said topical B244 met the primary endpoint of a greater proportion of patients who achieved a ≥2-point reduction in Investigator’s Global Assessment (IGA) score of acne severity from baseline to week...
15:44 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

AOBiome begins Phase Ib/IIa of B244 for allergic rhinitis

AOBiome LLC (Cambridge, Mass.) began a Phase Ib/IIa trial of B244 to treat seasonal allergic rhinitis. The double-blind, vehicle-controlled trial will enroll up to 24 healthy volunteers and up to 42 patients with a history...
19:53 , Jan 13, 2017 |  BC Week In Review  |  Company News

iCarbonX Digital Life Alliance news

iCarbonX said seven companies joined its Digital Life Alliance, through which it aims to combine genetic, biologic and patient-generated data with sequencing and artificial intelligence technology to "instantly detect meaningful signals about health, disease and...
23:52 , Jan 6, 2017 |  BC Extra  |  Company News

iCarbonX names Digital Health Alliance members

iCarbonX Inc. (Shenzhen, China) said seven companies joined its Digital Life Alliance, through which it aims to combine genetic, biologic and patient-generated data with sequencing and artificial intelligence technology to "instantly detect meaningful signals about...
22:20 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

B244: Ph II started

AOBiome began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily B244 topical spray comprising 8×109 colony forming units (CFUs)/mL for 28 days in 116 patients. AOBiome LLC, Cambridge, Mass.  Product: B244  Business: Cardiovascular  Molecular target: NA  Description: Live...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

B244: Phase IIb started

AOBiome began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 4x10 9 colony forming units (CFUs)/mL B244 topical spray administered to the face twice daily for 12 weeks in about 372 adult patients. The...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...